Earnings summaries and quarterly performance for Centessa Pharmaceuticals.
Executive leadership at Centessa Pharmaceuticals.
Saurabh Saha
Detailed
Chief Executive Officer
CEO
GW
Gregory Weinhoff
Detailed
Chief Business Officer
IH
Iqbal Hussain
Detailed
General Counsel
JC
John Crowley
Detailed
Chief Financial Officer
KA
Karen Anderson
Detailed
Chief People Officer
RD
Raphael Deferiere
Detailed
Chief Accounting Officer
SK
Steven Kanes
Detailed
Chief Medical Officer
TB
Tia Bush
Detailed
Chief Technology and Quality Officer
Board of directors at Centessa Pharmaceuticals.
Research analysts covering Centessa Pharmaceuticals.
Recent press releases and 8-K filings for CNTA.
Centessa Pharmaceuticals Provides Update on ORX750 Development and Pipeline Strategy
CNTA
New Projects/Investments
Guidance Update
Hiring
- Centessa Pharmaceuticals is transitioning into a pre-commercial stage company for rare hypersomnias and plans to initiate registrational studies for ORX750 in at least one, or potentially all three, indications (Narcolepsy Type 1, Type 2, and idiopathic hypersomnia) in Q1 2026.
- A Phase II update for at least one of these indications is anticipated in Q1 2026, with the company evaluating regulatory measures like Breakthrough Therapy Designation (BTD) to accelerate development.
- The company is advancing next-generation assets, ORX142 and ORX489 (with ORX489 entering the clinic in Q1 2026), for broader neuroscience indications and is hiring in commercial this year.
Feb 12, 2026, 6:00 PM
Centessa Pharmaceuticals outlines 2026 vision and ORX750 development plans
CNTA
New Projects/Investments
Product Launch
Guidance Update
- Centessa Pharmaceuticals anticipates 2026 to be a transformational year, evolving into a pre-commercial stage company for rare hypersomnias and a fully-fledged neurosciences company.
- The company intends to start registrational studies this quarter for its orexin agonist, ORX750, in at least one, and potentially all three, rare hypersomnia indications (Narcolepsy Type 1, Type 2, and idiopathic hypersomnia), having received positive feedback from the FDA.
- ORX750 has demonstrated a potential best-in-class profile across these indications, with the company aiming to maximize efficacy and provide dose flexibility to patients.
- Centessa is also progressing its pipeline with ORX142 and ORX489, the latter entering the clinic this quarter, which feature different pharmacokinetic profiles for broader neuroscience applications.
Feb 12, 2026, 6:00 PM
Centessa Pharmaceuticals Outlines 2026 Strategic Vision and ORX750 Registrational Study Plans
CNTA
New Projects/Investments
Hiring
- Centessa Pharmaceuticals plans to initiate registrational studies for its lead orexin agonist, ORX750, in at least one, and potentially all three, rare hypersomnia indications (narcolepsy type 1, type 2, and idiopathic hypersomnia) during Q1 2026.
- The company aims to be first in class in narcolepsy type 2 and idiopathic hypersomnia with ORX750, which demonstrated a potential best-in-class profile in November.
- Centessa is transitioning into a pre-commercial stage company for rare hypersomnias and expanding into a fully-fledged neurosciences company, with ORX142 entering the clinic in Q1 2026 to target broader neuroscience indications.
- The company has received positive feedback and alignment from the FDA regarding its clinical development strategy and is evaluating regulatory measures like Breakthrough Therapy Designation (BTD) to accelerate development.
Feb 12, 2026, 6:00 PM
Centessa Pharmaceuticals Provides Update on Orexin Agonist Programs and Phase 2 ORX750 Study
CNTA
Product Launch
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals highlighted its focus on orexin biology, with its lead asset ORX750 demonstrating clinically meaningful and statistically significant efficacy in initial Phase 2 cohorts for narcolepsy type 1, type 2, and idiopathic hypersomnia.
- The Phase 2 data for ORX750 showed a potential best-in-class profile with no adverse events limiting the therapeutic index, and only three cases of non-clinically meaningful, mild, and transient visual disturbances reported across 55 patients.
- The company is expanding its orexin agonist franchise with ORX142 and ORX489, both scheduled to enter Phase 1 studies in Q1 2026 for broader indications such as neurodegenerative and psychiatric disorders.
- Centessa anticipates providing a further update on the Phase 2 study and initiating its registrational program in Q1 2026.
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Future Orexin Program Milestones
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported clinically meaningful and statistically significant efficacy from initial cohorts of its ORX750 Phase 2 study in narcolepsy type 1, type 2, and idiopathic hypersomnia, indicating a potential best-in-class profile.
- Key efficacy results for ORX750 included a greater than 20-minute change from baseline on MWT for narcolepsy type 1 and a greater than 10-minute change from baseline on MWT (placebo adjusted) for narcolepsy type 2.
- Safety data across 55 patients for ORX750 showed only three mild, transient, non-clinically meaningful visual disturbances with no dose response.
- Centessa is advancing its orexin agonist franchise with ORX142 and ORX489, both scheduled to enter Phase 1 studies in Q1 2026 for broader indications such as neurodegenerative and psychiatric disorders.
- The company anticipates providing a further Phase 2 data update and initiating its registrational program for ORX750 in Q1 2026.
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Provides Update on Orexin Agonist Pipeline and ORX750 Phase II Data
CNTA
New Projects/Investments
Guidance Update
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Updates on Orexin Program and Clinical Development Timelines
CNTA
New Projects/Investments
Guidance Update
Product Launch
- Centessa Pharmaceuticals provided an update on its ORX750 Phase 2 study, demonstrating statistically significant and clinically meaningful efficacy across Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia (IH).
- In NT1, ORX750 showed a greater than 20-minute change from baseline in MWT and reduced ESS from 19 to 5, with cataplexy suppression to a 0.13 incidence rate ratio.
- For NT2, ORX750 achieved a greater than 10-minute change from baseline in MWT and reduced ESS from 15-16 to 8.
- The company plans to initiate the registration program (Phase 3) for ORX750 in Q1 2026 and will provide a further update on the next 50 patients in Q1 2026.
- Centessa is also advancing ORX142 into patient studies and ORX489 into Phase 1 studies, both in Q1 2026, aiming to expand beyond rare hypersomnias into broader neurodegenerative and psychiatric conditions.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Updates on Orexin Program and Future Milestones
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals provided an update on its ORX750 Phase II study, highlighting robust and statistically significant efficacy across narcolepsy type 1, type 2, and idiopathic hypersomnia, suggesting a potential best-in-class profile.
- The company plans to provide a further update on ORX750 data and commence its registrational program (Phase III) in Q1 2026.
- Centessa's pipeline includes additional orexin agonists, ORX142 and ORX489, both entering Phase I studies in Q1 2026, with the potential to address broader neurodegenerative and psychiatric conditions.
- The Orexin program is supported by homegrown intellectual property (IP), with protection extending past 2040.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Updates on Orexin Program Progress
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported robust Phase 2 data for its orexin agonist ORX750 across Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia (IH), demonstrating clinically and statistically significant efficacy.
- For NT1, ORX750 achieved a greater than 20-minute change from baseline in MWT and reduced ESS from 19 to 5; for NT2, it showed a greater than 10-minute change from baseline in MWT and reduced ESS from 15-16 to 8.
- The company plans to initiate the registration program (Phase 3) for ORX750 in Q1 2026, with an update on additional Phase 2 data expected in the same quarter.
- Centessa's pipeline includes ORX142 and ORX489, both entering Phase 1 studies in Q1 2026, aiming to expand beyond rare hypersomnias into neurodegenerative and psychiatric conditions.
- The company holds homegrown intellectual property for its small molecules, with protection extending past 2040.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Future Plans
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported positive Phase 2 data for ORX750 across narcolepsy type 1 (NT1), type 2 (NT2), and idiopathic hypersomnia (IH), demonstrating clinically and statistically significant efficacy and a potential best-in-class profile.
- ORX750 exhibited a clean safety profile with only three cases of transient and mild visual disturbances across 50 patients, and a pharmacokinetic profile supporting once-daily (QD) dosing with rapid onset and extended coverage.
- The company plans to start a registration program in Q1 2026 for ORX750, potentially across all three indications, and is continuing dose escalation in the ongoing Phase 2 study.
- Centessa estimates the market opportunity for NT1, NT2, and IH at approximately $18 billion and reported a proforma balance sheet of $620 million.
Nov 18, 2025, 2:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more